You searched for side effects - Page 77 of 311 - Medivizor
Navigation Menu

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Posted by on Nov 2, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL).  This study concluded that this combination was well tolerated and had promising...

Read More

Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia

Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia

Posted by on Oct 30, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL).  This study concluded that both treatments are safe and effective as a...

Read More

Evaluating osimertinib for EGFR positive non-small-cell lung cancer that was surgically removed.

Evaluating osimertinib for EGFR positive non-small-cell lung cancer that was surgically removed.

Posted by on Oct 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness and safety of osimertinib (Tagrisso) after surgery for EGFR-positive advanced non-small cell lung cancer (NSCLC). The trial found that this treatment improved the outcomes of patients with stage IB to IIIA EGFR-positive NSCLC that was surgically removed. Some...

Read More

Comparing the outcomes of carfilzomib once-weekly vs twice-weely in patients with relapsed/refractory multiple myeloma

Comparing the outcomes of carfilzomib once-weekly vs twice-weely in patients with relapsed/refractory multiple myeloma

Posted by on Oct 29, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study compared outcomes of once-weekly (OW) versus twice-weekly (TW) carfilzomib (Kyprolis) plus dexamethasone (Decadron) in Japanese patients with relapsed/refractory (RR) multiple myeloma (MM). The authors found that the OW dosage improved overall response rate (ORR) compared to TW in such patients. Some background RR-MM...

Read More

Increasing solifenacin dose is effective and safe for male patients with unresponsive overactive bladder

Increasing solifenacin dose is effective and safe for male patients with unresponsive overactive bladder

Posted by on Oct 29, 2020 in Overactive bladder | 0 comments

In a nutshell This study investigated the effectiveness and safety of increasing the dose of solifenacin (Vesicare) treatment in male patients with overactive bladder (OAB) that does not respond to low-dose treatment. Researchers suggested that increasing the dose of solifenacin is safe and improves the outcomes of these patients. Some...

Read More

Longer survival without progression in patients with NSCLC with nivolumab plus chemotherapy before surgery

Longer survival without progression in patients with NSCLC with nivolumab plus chemotherapy before surgery

Posted by on Oct 25, 2020 in Lung cancer | 0 comments

In a nutshell This study investigated the antitumor activity, safety, and survival after nivolumab (Opdivo) and chemotherapy before surgery for patients with stage IIIA non-small-cell lung cancer (NSCLC). The study showed a high rate of survival without cancer worsening among these patients. Some background NSCLC amounts to over 80% of...

Read More

Pembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma

Pembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma

Posted by on Oct 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of pembrolizumab (Keytruda) followed by AVD (doxorubicin, vinblastine, and dacarbazine) treatment in patients with high-risk classical Hodgkin lymphoma.  This study concluded that this treatment was safe and effective in these patients.   Some...

Read More

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Posted by on Oct 24, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated longer-term survival rates and the safety of olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC). It found that treatment with olaparib led to significantly longer survival, especially in men with gene alterations. Some background CRPC is an especially aggressive...

Read More

Evaluating the timing of chemotherapy plus bevacizumab for patients with colorectal cancer and liver metastasis

Evaluating the timing of chemotherapy plus bevacizumab for patients with colorectal cancer and liver metastasis

Posted by on Oct 24, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated whether chemotherapy plus bevacizumab (Avastin) before and after or after surgery improves the survival of patients with colorectal cancer (CRC) and operable liver metastasis (LM; cancer spread to the liver). Researchers suggested that chemotherapy and bevacizumab before and after...

Read More